Patient demographics and characteristics of patients with FA who did not undergo HSCT
| . | Non-HSCT, PLI (n = 10) . | Non-HSCT, no PLI (n = 37) . | P value . |
|---|---|---|---|
| Sex, n (%) | |||
| Female | 6 (60) | 17 (45.9) | .49 |
| Male | 4 (40) | 20 (54.1) | |
| Race, n (%) | |||
| Caucasian | 10 (100) | 36 (97.3) | 1.0 |
| African American | 0 | 0 | |
| Hispanic | 0 | 1 (2.7) | |
| Asian | 0 | 0 | |
| Age (y) at first evaluation, median (IQR) | 11.9 (2.5-15.7) | 4.2 (2.6-10.5) | .28 |
| FANC complementation group, n (%) | |||
| FANCA | 4 (40) | 29 (78.3) | .045 |
| Non-FANCA | 6 (60) | 7 (18.9) | |
| Unknown | 0 | 1 (2.8) | |
| Prior androgen use, n (%) | 2 (20) | 2 (5.4) | .19 |
| Survival, n (%) | |||
| Alive | 9 (90%) | 37 (100) | .26 |
| . | Non-HSCT, PLI (n = 10) . | Non-HSCT, no PLI (n = 37) . | P value . |
|---|---|---|---|
| Sex, n (%) | |||
| Female | 6 (60) | 17 (45.9) | .49 |
| Male | 4 (40) | 20 (54.1) | |
| Race, n (%) | |||
| Caucasian | 10 (100) | 36 (97.3) | 1.0 |
| African American | 0 | 0 | |
| Hispanic | 0 | 1 (2.7) | |
| Asian | 0 | 0 | |
| Age (y) at first evaluation, median (IQR) | 11.9 (2.5-15.7) | 4.2 (2.6-10.5) | .28 |
| FANC complementation group, n (%) | |||
| FANCA | 4 (40) | 29 (78.3) | .045 |
| Non-FANCA | 6 (60) | 7 (18.9) | |
| Unknown | 0 | 1 (2.8) | |
| Prior androgen use, n (%) | 2 (20) | 2 (5.4) | .19 |
| Survival, n (%) | |||
| Alive | 9 (90%) | 37 (100) | .26 |